Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,784 people get ATRS articles and Market Currents by email alert.
Get email alerts on ATRS »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Business Wire (May 29, 2013)
-
Business Wire (May 24, 2013)
-
Business Wire (May 23, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Apr 3, 2013)
-
Business Wire (Mar 13, 2013)
-
Business Wire (Mar 6, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 20, 2013)
-
at CNBC.com (Jan 16, 2013)
-
Business Wire (Dec 17, 2012)
-
Business Wire (Dec 5, 2012)
-
at CNBC.com (Dec 3, 2012)
-
Business Wire (Nov 13, 2012)
ATRS vs. ETF Alternatives
Company Description
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide. The companyÂ’s products include Tjet/Zomajet, the needle-free auto... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 7:10 AM Antares Pharmaceuticals (ATRS): Q1 EPS of -$0.03 in-line. Revenue of $4.53M misses by $0.59M. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
- Friday, April 5, 8:01 AM Antares Pharma (ATRS) gets a Notice of Allowance from the U.S. Patent Trade Office regarding the company's patent application for the VIBEX QuickShot. ATRS said Thursday that the first shipment of the auto-injector devices will be on their way to Teva (TEVA) by the end of Q1. Shares +2% premarket. 1 Comment [Healthcare, On the Move]
- Wednesday, April 3, 12:37 PM Antares Pharma (ATRS +0.3%) says the first shipment of commercial-ready VIBEX auto-injector devices will be shipped to TEVA at the end of Q1. Anatares will receive a negotiated purchase price for each device sold, as well as a royalty on sales. 1 Comment [Healthcare, Global & FX]
- Wednesday, March 13, 7:02 AM Antares Pharma (ATRS): Q4 EPS of -$0.04 misses by $0.01. Revenue of $5.5M beats by $0.14M. (PR) 6 Comments [Earnings, Breaking News, Healthcare]
- Wednesday, March 13, 12:05 AM Notable earnings before Wednesday’s open: AH, AMRC, ATRS, EXPR, KRO, PERI, SNSS, TA Comment! [Earnings]
- Tuesday, March 12, 5:30 PM Notable earnings before Wednesday’s open: AH, AMRC, ATRS, EXPR, KRO, PERI, SNSS, TA Comment! [Earnings]
- Tuesday, November 13, 2012, 8:44 AM Antares Pharma's (ATRS) MTX Medi-Jet injection device performed well in treating rheumatoid arthritis sufferers with Methotrexate compared with the oral version of the medicine. The MTX Medi-Jet enables patients with difficulty using their hands to inject the treatment into themselves, thereby avoiding the need for weekly injections by a professional. (PR) 1 Comment [Healthcare]
- Wednesday, November 7, 2012, 7:56 AM Altiris (ATRS): Q3 EPS of -$0.03 misses by $0.01. Revenue of $5.7M (+45% Y/Y) in-line. Shares -4.2% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
-
Wednesday, October 3, 2012, 12:45 PM
Midday top 10 gainers: SRPT +162%. BIOL +38%. VRNG +25%. OCN +16%. KFS +16%. ASPS +14%. SNFCA +12%. TRU +10%. HOV +10%. ICAD +10%.
Top 10 Losers: GST -21%. LEAP -16%. XRTX -15%. THTI -13%. PBM -12%. SSY -10%. HOLL -10%. KRA -10%. ATRS -9%. KIOR -9%. 2 Comments [On the Move] - Wednesday, October 3, 2012, 9:41 AM Antares Pharma (ATRS) slumps 7.4% to $4.07 after pricing an offering of 12.5M shares at $4 each, resulting in net proceeds of $47M. The underwriters have a 30-day option to buy up to 1.875M extra shares. (PR) 1 Comment [Healthcare, On the Move]
-
Wednesday, October 3, 2012, 9:10 AM
Premarket gainers: SRPT +107%. BIOL +14%. GENE +13%. ROYL +9%.
Losers: XRTX -9%. ATRS -7%. RIGL -6%. Comment! [On the Move] - Tuesday, September 25, 2012, 11:46 AM Antares Pharma (ATRS +11%) jumps after reporting positive results from its Actual Human Use study, to assess the effectiveness of self-administered Vibex Methotrexate for adult patients with rheumatoid arthritis. The company said that the results show that self-administration of the drug is safe and well tolerated. All 101 patients were able to self-administer the medication successfully following standardized training and review of written instructions. 4 Comments [Healthcare, On the Move]
-
Tuesday, September 25, 2012, 9:10 AM
Premarket gainers: GENE +14%. DARA +13%. PPHM +8%. ATRS +8%. PURE +6%. UDRL +6%. ROSG +6%.
Losers: GEVO -16%. TSLA -8%. KEG -8%. Comment! [On the Move] - Friday, August 10, 2012, 1:36 PM Shares of Antares Pharma (ATRS -9.1%) continue their slide today after its second-quarter loss widened and results missed analyst estimates on Wednesday. Net profit was hit by bottom line pressure from higher investment expenses related to the development of its Vibex MTX auto injector for the treatment of rheumatoid arthritis, along with an increase in support personnel. 9 Comments [Healthcare, On the Move]
-
Friday, August 10, 2012, 9:10 AM
Premarket gainers: FIO +23%. JNS +18%. XIN +14%. BYI +7%. RIMM +6%.
Losers: UBNT -39%. RNDY -22%. SPRD -13%. PIP -11%. ATRS -6%. CPST -6%. DK -5%. Comment! [On the Move] -
Wednesday, August 8, 2012, 9:10 AM
Premarket gainers: WFR +31%. DF +28%. RAX +14%. LAMR +13%. CBB +12%. SODA +8%. CLWR +7%. KTOS +7%. ESRX +6%. HPQ +6%.
Losers: EZCH -21%. GIVN -16%. PCLN -15%. ATRS -9%. ASTM -9%. WCRX -8%. RL -7%. EXAS -5%. RENN -5%. Comment! [On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
Scott Matusow
My new article out at http://seekingalpha.com/a/vczn New Vid at http://bit.ly/19jbbZn $ATRS $BDSI - View all 1 replies
-
-
bull_market_somewhere
been in $ATRS since 2010 (when it was $AIS), looking for a big move or a buyout eventually. - View all 3 replies
-
bull_market_somewhere: this year has been a nailbiter, very range bound.
-
gbstern13: Don't get impatient. You've likely doubled since 2010, some possible catalysts in next year, little short term risk. Stay the course.
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 6 replies
-
JoeChang23: Don't underestimate AF, he was rite many times & saved many retail investors from catastrophic stocks such as CLSN, CPRX, AMRN, PPHM.
-
jsiebel720: ATRS is not a risky cancer or drug biotech company; Its profile is different; maybe you can give AF some credibility, but Cramer has none.
-
- View all 0 replies
-
Shadow Play
I see $ATRS meditating from the 3.60's-4.10's until late January. Once the Vibex MTX filing comes to light with FDA, then it pushes to $5. - View all 0 replies
-
- View all 4 replies
-
TDPeterson123: Thanks, Scott. The Teva investor conference on 12/11 could also be a catalyst event to ATRS (some speculate significantly so).
-
TDPeterson123: Until the "Fiscal Cliff" ordeal reaches some sort of resolution we'll see a volatile market. 11th hour if it gets resolved this year.
LATEST REPLIES
-
Scott Matusow
My new article out at http://seekingalpha.com/a/vczn New Vid at http://bit.ly/19jbbZn $ATRS $BDSI - View all 1 replies
-
-
bull_market_somewhere
been in $ATRS since 2010 (when it was $AIS), looking for a big move or a buyout eventually. - View all 3 replies
-
bull_market_somewhere: this year has been a nailbiter, very range bound.
-
gbstern13: Don't get impatient. You've likely doubled since 2010, some possible catalysts in next year, little short term risk. Stay the course.
-
- View all 6 replies
-
JoeChang23: Don't underestimate AF, he was rite many times & saved many retail investors from catastrophic stocks such as CLSN, CPRX, AMRN, PPHM.
-
jsiebel720: ATRS is not a risky cancer or drug biotech company; Its profile is different; maybe you can give AF some credibility, but Cramer has none.
-
- View all 2 replies
-
-
-
- View all 4 replies
-
TDPeterson123: Thanks, Scott. The Teva investor conference on 12/11 could also be a catalyst event to ATRS (some speculate significantly so).
-
TDPeterson123: Until the "Fiscal Cliff" ordeal reaches some sort of resolution we'll see a volatile market. 11th hour if it gets resolved this year.
-
Cabeza Howe
$ATRS: $3.60 (-7.1%) in a day. But one year from now you will be happy you bought in today. - View all 6 replies
-
Cabeza Howe: After counting cash take-in from options/warrants exercises, annual cash burn rate is only $1.5M. Also biotechs not sensitive to economy.
-
Cabeza Howe: It's the fears that's driving all small biopharmas lower regardless of quality. Whoever buys quality will be rewarded over time.
-
- View all 3 replies
-
-
-
Joe Springer
Here's the latest $33,000 article, we stand at $35,814.50 http://seekingalpha.com/a/kltb $PSTI $SPPI $ARNA $ACI $MNKD $IBIO $ATRS #Sandy - View all 3 replies
-
Joe Springer: Hi IV, May 25 was start, I try to limit the trades so that it is replicable, 2 month average per trade about: http://seekingalpha.com/p/e7pf
-
-
- View all 5 replies
-
-
-
- View all 1 replies
-
-
Scott Matusow
My explanation why I sold Antares (ATRS) + some charting analysis and commentary...: http://bit.ly/QIwlHV - View all 12 replies
-
-
-
Scott Matusow
$FOLD Chart and opinion, Further $ATRS commentary. To start, I remark I am still bullish on Antares @ http://bit.ly/Q0yD3t - View all 3 replies
-
-
-
Scott Matusow
$ATRS is my best long term investment pick concerning small caps. $23 - $25 a share price target in 2015 - View all 27 replies
-
-
-
- View all 17 replies
-
-
-
- View all 7 replies
-
spybreaker: yeah, must be one of those "feel good" effects. It's going nuts now - up 2.38% premarket. -